Ubs Asset Management Americas Inc Syndax Pharmaceuticals Inc Transaction History
Ubs Asset Management Americas Inc
- $345 Billion
- Q2 2024
A detailed history of Ubs Asset Management Americas Inc transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 153,360 shares of SNDX stock, worth $3.05 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
153,360
Previous 96,833
58.38%
Holding current value
$3.05 Million
Previous $2.3 Million
36.63%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding SNDX
# of Institutions
202Shares Held
87.1MCall Options Held
268KPut Options Held
76.8K-
Black Rock Inc. New York, NY7.91MShares$157 Million0.0% of portfolio
-
Wellington Management Group LLP Boston, MA7.34MShares$146 Million0.03% of portfolio
-
Kynam Capital Management, LP Princeton, NJ5.72MShares$114 Million9.15% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.8MShares$95.4 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY3.89MShares$77.3 Million1.09% of portfolio
About Syndax Pharmaceuticals Inc
- Ticker SNDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,565,200
- Market Cap $1.13B
- Description
- Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...